James Butler

Dr. James Butler

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
JBJames Butler
James Butler
JDJennifer B. Dressman
Jennifer B. Dressman

1 October 2016 in Drug Discovery Today
Verified
Journal Article
Closed access
MBMartin K. Bayliss
Martin K. Bayliss
JBJames Butler
James Butler
PFPaul L. Feldman
Paul L. Feldman
DGDarren V.S. Green
Darren V.S. Green
PLPaul D. Leeson
Paul D. Leeson
ATAnthony J. Taylor
Anthony J. Taylor

23 August 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
JMJames Mann
James Mann
JDJennifer Dressman
Jennifer Dressman
KRKarin Rosenblatt
Karin Rosenblatt
LALee Ashworth
Lee Ashworth
UMUwe Muenster
Uwe Muenster
JBJames Butler
James Butler

1 July 2020 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
BAB. Abrahamsson
B. Abrahamsson
MMM. McAllister
M. McAllister
PAPatrick Augustijns
Patrick Augustijns
PZP. Zane
P. Zane
JBJames Butler
James Butler
HLHans Lennernäs
Hans Lennernäs
OrBiTo was a precompetitive collaboration focused on the development of the next generation of Oral Biopharmaceutics Tools. The consortium included world leading scientists from nine universities, one regulatory agency, one non-profit research organisation, three small/medium sized specialist technology companies together with thirteen pharmaceutical companies. The goal of the OrBiTo project was to deliver a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This goal was achieved through novel prospective investigations to define new methodologies or refinement of existing tools. Extensive validation has been performed of novel and existing biopharmaceutics tools using historical datasets supplied by industry partners as well as laboratory ring studies. A combination of high quality in vitro and in vivo characterizations of active drugs and formulations have been integrated into physiologically based in silico biopharmaceutics models capturing the full complexity of gastrointestinal drug absorption and some of the best practices has been highlighted. This approach has given an unparalleled opportunity to deliver transformational change in European industrial research and development towards model based pharmaceutical product development in accordance with the vision of model-informed drug development.

28 January 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
ABAlice Brookes
Alice Brookes
AJAdelaide Jewell
Adelaide Jewell
WFWanshan Feng
Wanshan Feng
TBTracey Bradshaw
Tracey Bradshaw
JBJames Butler
James Butler
PGPavel Gershkovich
Pavel Gershkovich
Delivery to the brain is a challenging task due to its protection by the blood-brain barrier (BBB). Lipids and fatty acids are reported to affect the permeability of the BBB, although this has not been reported following oral administration. Cannabidiol (CBD) has high therapeutic potential in the brain, therefore, this work investigated CBD delivery to anatomical brain regions following oral administration in lipid-based and lipid-free vehicles. All formulations resulted in a short brain Tmax (1 h) and brain-plasma ratios ≥ 3.5, with retention up to 18 h post administration. The highest CBD delivery was observed in the olfactory bulb and striatum, and the medulla pons and cerebellum the lowest. The lipid-free vehicle led to the highest levels of CBD in the whole brain. However, when each anatomical region was assessed individually, the long chain triglyceride-rich rapeseed oil formulation commonly showed optimal performance. The medium chain triglyceride-rich coconut oil formulation did not result in the highest CBD concentration in any brain region. Overall, differences in CBD delivery to the whole brain and various brain regions were observed following administration in different formulations, indicating that the oral formulation selection may be important for optimal delivery to specific regions of the brain.

30 March 2022 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
AJAdelaide Jewell
Adelaide Jewell
ABAlice Brookes
Alice Brookes
WFWanshan Feng
Wanshan Feng
MAMarianne Ashford
Marianne Ashford
PGPaul Gellert
Paul Gellert
PGPavel Gershkovich
Pavel Gershkovich
Efficient delivery of highly lipophilic drugs or prodrugs to the mesenteric lymph nodes (MLN) can be achieved following oral administration with lipids. However, it remains unclear which specific MLN can be targeted and to what extent. Moreover, the efficiency of drug delivery to the retroperitoneal lymph nodes (RPLN) has not been assessed. The aim of this study was to assess the distribution of a highly lipophilic model drug cannabidiol (CBD), known to undergo intestinal lymphatic transport following administration with lipids, into specific MLN and RPLN in rats at various time-points post dosing. In vivo studies showed that at 2 h following administration, significantly higher concentrations of CBD were present in the region second from the apex of the MLN chain. From 3 h following administration, concentrations in all MLN were similar. CBD was also found at substantial levels in RPLN. This study demonstrates that drug concentrations in specific MLN are different, at least at the peak of the absorption process. Moreover, in addition to the MLN, the RPLN may also be targeted by oral route of administration, which may have further implications for treatment of a range of diseases.